NEW YORK (360Dx) – Rosetta Genomics said that it recorded $330,000 in revenues for the RosettaGX Reveal thyroid miRNA classifier during October, which would represent a $4 million annual revenue run rate. The test classifies indeterminate thyroid nodules. The company said the revenue ramp is partly attributable to record commercial collections driven by increased sample volumes and higher per-claim payments. The test recorded $860,000 in revenues during the third quarter.
Avista Capital Partners has completed its acquisition of Miraca Life Sciences from Miraca Holdings. The deal was originally announced in September. Miraca is an independent anatomic pathology lab providing subspecialty anatomic pathology services in gastroenterology, dermatology, hematology, breast health, and urology. Its pathologists serve more than 3,000 physicians and 5,500 patients daily. Also, Scott Walton has been appointed CEO of Miraca.
AccuRef Diagnostics announced its formation as a new division under Applied StemCell, a global provider of molecular and cellular reference standards for assay development, proficiency testing, and quality control.
ARD said that it continues to expand its product catalog to generate a panel of precision engineered reference standards, with more than 215 CRISPR-engineered variants in its oncology catalog, and greater than 1,500 products.
The firm's Director of Marketing Gianluca Roma said that its "ultimate goal is to create a broad portfolio of high-value reference standards for routine use on multiple analysis platforms and for multiple clinical diagnostics applications.”
Becton Dickinson’s board has declared a quarterly dividend of $.75 per share, payable on Dec. 29 to shareholders of record on Dec. 8. The indicated annual dividend rate for fiscal 2018 is $3 per share, the firm said.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the 360Dx site.